Skip to content
10-Q

Quarterly Report

Metagenomi Therapeutics, Inc. MGX

0001193125-26-216774

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 37.65M sh
Shares Diluted Q1 2026 · Mar 31, 2026 37.58M sh
Shares Diluted Q1 2026 · Mar 31, 2025 37.02M sh
Capex Q1 2026 · Mar 31, 2026 $25K
Capex Q1 2026 · Mar 31, 2025 $288K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$21.18M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$22.84M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $25.31M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $41.72M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $29.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $137.79M
Stockholders Equity Q1 2026 · Dec 31, 2025 $158.6M
Stockholders Equity Q1 2026 · Mar 31, 2025 $212.66M
Stockholders Equity Q1 2026 · Dec 31, 2024 $234.86M
Current Liabilities Q1 2026 · Mar 31, 2026 $22.5M
Current Liabilities Q1 2026 · Dec 31, 2025 $22.93M
Total Liabilities Q1 2026 · Mar 31, 2026 $59.17M
Total Liabilities Q1 2026 · Dec 31, 2025 $62.51M
Current Assets Q1 2026 · Mar 31, 2026 $144.56M
Current Assets Q1 2026 · Dec 31, 2025 $165.54M
Total Assets Q1 2026 · Mar 31, 2026 $196.95M
Total Assets Q1 2026 · Dec 31, 2025 $221.1M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.61
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.68
Eps Basic Q1 2026 · Mar 31, 2026 −$0.61
Eps Basic Q1 2026 · Mar 31, 2025 −$0.68
Sga Expense Q1 2026 · Mar 31, 2026 $6.54M
Sga Expense Q1 2026 · Mar 31, 2025 $6.81M
Rd Expense Q1 2026 · Mar 31, 2026 $19.3M
Rd Expense Q1 2026 · Mar 31, 2025 $25.14M
Net Income Q1 2026 · Mar 31, 2026 −$23.06M
Net Income Q1 2026 · Mar 31, 2025 −$25.04M
Operating Income Q1 2026 · Mar 31, 2026 −$24.59M
Operating Income Q1 2026 · Mar 31, 2025 −$27.82M
Revenue Q1 2026 · Mar 31, 2026 $1.25M
Revenue Q1 2026 · Mar 31, 2025 $4.13M